Existing shareholders have provided additional funding to Abingdon Health, which is developing a test for multiple myeloma.

Abingdon Health, a UK-based medical device maker based on research at University of Birmingham, raised £1.1m ($1.5m) from current shareholders in the company.

While the company did not further clarify the identity of the investors, its existing backers include Touchstone Innovations, the commercialisation firm spun out of Imperial College London that was acquired by its peer IP Group last month.

Abingdon has developed Seralite, a rapid test for the diagnosis and management of patients suffering from a type of…